Rahman M, Khatun A, Liu L, Barkla B
Int J Mol Sci. 2024; 25(16).
PMID: 39201724
PMC: 11354652.
DOI: 10.3390/ijms25169039.
Mehta A, Prabhu M, Krishnan G
BMJ Case Rep. 2021; 14(11).
PMID: 34848406
PMC: 8634231.
DOI: 10.1136/bcr-2021-244757.
Murru E, Carta G, Manca C, Sogos V, Pistis M, Melis M
Front Pharmacol. 2021; 11:587140.
PMID: 33505308
PMC: 7832089.
DOI: 10.3389/fphar.2020.587140.
Chhajed R, Thomas T, Swaminathan S, Kurpad A, Mani I
Public Health Nutr. 2020; 24(15):4869-4877.
PMID: 33190676
PMC: 11094388.
DOI: 10.1017/S1368980020004632.
Turk B, Theda C, Fatemi A, Moser A
Int J Dev Neurosci. 2020; 80(1):52-72.
PMID: 31909500
PMC: 7041623.
DOI: 10.1002/jdn.10003.
Late onset adrenoleukodystrophy: A review related clinical case report.
Palau-Hernandez S, Rodriguez-Leyva I, Shiguetomi-Medina J
eNeurologicalSci. 2019; 14:62-67.
PMID: 30671550
PMC: 6330384.
DOI: 10.1016/j.ensci.2019.01.007.
A model-based approach to assess the exposure-response relationship of Lorenzo's oil in adrenoleukodystrophy.
Ahmed M, Kartha R, Brundage R, Cloyd J, Basu C, Carlin B
Br J Clin Pharmacol. 2016; 81(6):1058-66.
PMID: 26836218
PMC: 4876192.
DOI: 10.1111/bcp.12897.
A mixture of oleic, erucic and conjugated linoleic acids modulates cerebrospinal fluid inflammatory markers and improve somatosensorial evoked potential in X-linked adrenoleukodystrophy female carriers.
Cappa M, Bizzarri C, Petroni A, Carta G, Cordeddu L, Valeriani M
J Inherit Metab Dis. 2011; 35(5):899-907.
PMID: 22189598
PMC: 3432215.
DOI: 10.1007/s10545-011-9432-3.
Is subclinical adrenal failure in adrenoleukodystrophy/adrenomyeloneuropathy reversible?.
Cappa M, Bizzarri C, Giannone G, Aiello C, di Biase A
J Endocrinol Invest. 2011; 34(10):753-6.
PMID: 21399389
DOI: 10.3275/7570.
Erucic acid is differentially taken up and metabolized in rat liver and heart.
Murphy C, Murphy E, Golovko M
Lipids. 2008; 43(5):391-400.
PMID: 18350328
DOI: 10.1007/s11745-008-3168-3.
"Lorenzo's oil" therapy for X-linked adrenoleukodystrophy: rationale and current assessment of efficacy.
Moser H, Moser A, Hollandsworth K, Brereton N, Raymond G
J Mol Neurosci. 2007; 33(1):105-13.
PMID: 17901554
DOI: 10.1007/s12031-007-0041-4.
Evaluation of therapy of X-linked adrenoleukodystrophy.
Moser H, Fatemi A, Zackowski K, Smith S, Golay X, Muenz L
Neurochem Res. 2004; 29(5):1003-16.
PMID: 15139299
DOI: 10.1023/b:nere.0000021245.12181.90.
Pex13 inactivation in the mouse disrupts peroxisome biogenesis and leads to a Zellweger syndrome phenotype.
Maxwell M, Bjorkman J, Nguyen T, Sharp P, Finnie J, Paterson C
Mol Cell Biol. 2003; 23(16):5947-57.
PMID: 12897163
PMC: 166343.
DOI: 10.1128/MCB.23.16.5947-5957.2003.
Metabolism of trideuterated iso-lignoceric acid in rats in vivo and in human fibroblasts in culture.
Poulos A, Stockham P, Johnson D, Paton B, Beckman K, Singh H
Lipids. 1999; 34(9):943-9.
PMID: 10574659
DOI: 10.1007/s11745-999-0444-y.
Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".
van Geel B, Assies J, Haverkort E, Koelman J, Verbeeten Jr B, Wanders R
J Neurol Neurosurg Psychiatry. 1999; 67(3):290-9.
PMID: 10449548
PMC: 1736534.
DOI: 10.1136/jnnp.67.3.290.
A mouse model for X-linked adrenoleukodystrophy.
Lu J, Lawler A, Watkins P, Powers J, Moser A, Moser H
Proc Natl Acad Sci U S A. 1997; 94(17):9366-71.
PMID: 9256488
PMC: 23196.
DOI: 10.1073/pnas.94.17.9366.
X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.
van Geel B, Assies J, Wanders R, Barth P
J Neurol Neurosurg Psychiatry. 1997; 63(1):4-14.
PMID: 9221959
PMC: 2169642.
DOI: 10.1136/jnnp.63.1.4.
Effects of exogenous hexacosanoic acid on biochemical myelin composition in weaning and post-weaning rats.
di Biase A, Avellino C, Pieroni F, Quaresima T, Grisolia A, Cappa M
Neurochem Res. 1997; 22(3):327-31.
PMID: 9051669
DOI: 10.1023/a:1022451108063.
Very long-chain fatty acids in diagnosis, pathogenesis, and therapy of peroxisomal disorders.
Moser H, Moser A
Lipids. 1996; 31 Suppl:S141-4.
PMID: 8729109
DOI: 10.1007/BF02637066.
Oxidation of pristanic acid in fibroblasts and its application to the diagnosis of peroxisomal beta-oxidation defects.
Paton B, Sharp P, Crane D, Poulos A
J Clin Invest. 1996; 97(3):681-8.
PMID: 8609223
PMC: 507104.
DOI: 10.1172/JCI118465.